Furthermore, by performing IHC staining using mouse tumor tissues, we found that SR9009 treatment reduced the expression of FOXM1 and its target genes CCNB1, CCNB2 and Survivin (Fig. 7F). This evidence concerns the gene FOXM1 and neoplasm.